These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37352112)

  • 1. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
    Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.
    Tini G; Cuomo A; Battistoni A; Sarocchi M; Mercurio V; Ameri P; Volpe M; Porto I; Tocchetti CG; Spallarossa P
    Int J Cardiol; 2022 Feb; 349():134-137. PubMed ID: 34848212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
    Di Lisi D; Madaudo C; Alagna G; Santoro M; Rossetto L; Siragusa S; Novo G
    ESC Heart Fail; 2022 Jun; 9(3):1914-1919. PubMed ID: 35355425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Rivero-Santana B; Saldaña-García J; Caro-Codón J; Zamora P; Moliner P; Martínez Monzonis A; Zatarain E; Álvarez-Ortega C; Gómez-Prieto P; Pernas S; Rodriguez I; Buño Soto A; Cadenas R; Palacios Ozores P; Pérez Ramírez S; Merino Salvador M; Valbuena S; Fernández Gasso L; Juárez V; Severo A; Terol B; de Soto Álvarez T; Rodríguez O; Brion M; González-Costello J; Canales Albendea M; González-Juanatey JR; Moreno R; López-Sendón J; López-Fernández T
    Eur Heart J; 2024 Aug; ():. PubMed ID: 39106857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies.
    Vakilpour A; Lefebvre B; Lai C; Scherrer-Crosbie M
    Blood Rev; 2024 Mar; 64():101166. PubMed ID: 38182490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A
    Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction to: Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Eur J Prev Cardiol; 2023 Dec; 30(18):2044. PubMed ID: 37699074
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study.
    Hubbert L; Mallios P; Karlström P; Papakonstantinou A; Bergh J; Hedayati E
    Front Oncol; 2023; 13():1095251. PubMed ID: 37152049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
    Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
    Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.
    Fernando F; Andres MS; Claudiani S; Kermani NZ; Ceccarelli G; Innes AJ; Khan A; Rosen SD; Apperley JF; Lyon AR; Milojkovic D
    Cardiooncology; 2024 Jul; 10(1):42. PubMed ID: 39010172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of haematologic malignancies and survival outcomes of adult lymphomas in Maiduguri, north eastern Nigeria--a fourteen year review.
    Kagu MB; Ahmed SG; Bukar AA; Mohammed AA; Mayun AA; Musa AB
    Afr J Med Med Sci; 2013 Mar; 42(1):5-14. PubMed ID: 23909089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
    Cronin M; Crowley A; Davey MG; Ryan P; Abdelshafy M; Elkoumy A; Elzomor H; Arsang-Jang S; Ganly S; Nash P; Crowley J; Sharif F; Simpkin A; Lowery A; Wijns W; Kerin M; Soliman O
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Italian cancer figures, report 2012: Cancer in children and adolescents.
    ; ;
    Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
    Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
    Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.
    Lancellotti P; Anker SD; Donal E; Edvardsen T; Popescu BA; Farmakis D; Filippatos G; Habib G; Maggioni AP; Jerusalem G; Galderisi M
    Eur Heart J Cardiovasc Imaging; 2015 May; 16(5):466-70. PubMed ID: 25744342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival for patients with rare haematologic malignancies: Changes in the early 21st century.
    Pulte D; Weberpals J; Jansen L; Luttmann S; Holleczek B; Nennecke A; Ressing M; Katalinic A; Brenner H;
    Eur J Cancer; 2017 Oct; 84():81-87. PubMed ID: 28800491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.